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Abstract: 
 
Background: The rising global emergence of Gram-negative bacteria (GNB) producing β-lactam hydrolysing enzymes 
in clinical infections constitutes a growing public health threat. This study investigated the occurrence of co-production 
of extended spectrum β-lactamase (ESβL), AmpC β-lactamases, and carbapenemases among GNB isolated from HIV-
infected patients in two tertiary healthcare facilities in southwest Nigeria.  
Methodology: A total of 115 GNB isolates previously recovered from HIV-infected patients at the Obafemi Awolowo 
University Teaching Hospitals Complex, Ile-Ife, and the State Specialist Hospital, Akure, were investigated. The 
isolates were characterized to species level with the Microbact 24E kit and screened for ESβL production using the 
double-disc test (DDT) and combination disc methods, AmpC using modified Hodge test (MHT) and AmpC EDTA disc, 
and carbapenemase production using the MHT and EDTA disc test. Antibiotic susceptibility testing (AST) was 
performed by the Kirby-Bauer disc diffusion method.  
Results: A total of 15 species of GNB were characterized. The AST profile of the isolates revealed high resistance 
rates to ampicillin (94.5%), tetracycline (74.5%), sulphamethoxazole-trimethoprim (66.3%), and lowest resistance 
to imipenem (10.9%). Multi-drug resistance (MDR) was observed in 93.6% while 98.8% of ESβL, AmpC, and 
carbapenemase-producing isolates had multiple antibiotic resistance (MAR) indices ≥ 0.2. ESβL production was 
detected in 53.9%, AmpC in 20.9% and carbapenemase in 25.2% of the isolates. ESβL, AmpC or carbapenemase or 
co-production of two or all three enzymes was detected in 80 (69.6%) isolates, while only 10.0% produced all three 
enzymes.  
Conclusion: The isolation of MDR bacteria and isolates co-producing β-lactam hydrolysing enzymes in 
immunocompromised individuals portend grave consequences. Routine screening for these enzymes in MDR bacteria 
will be highly essential to guide the institution of appropriate antibiotic therapy and infection control measures.  
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Abstrait:  
Contexte: L'émergence mondiale croissante de bactéries à Gram négatif (GNB) produisant des enzymes d'hydrolyse 
de β-lactame dans les infections cliniques constitue une menace croissante pour la santé publique. Cette étude a 
examiné l'occurrence de la coproduction de β-lactamases à spectre étendu (ESβL), de β-lactamases AmpC et de 
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carbapénémases parmi les GNB isolés de patients infectés par le VIH dans deux établissements de santé tertiaires du 
sud-ouest du Nigéria.                                                   
Méthodologie: Un total de 115 isolats de GNB précédemment récupérés de patients infectés par le VIH au complexe 
hospitalier universitaire Obafemi Awolowo, Ile-Ife, et au State Specialist Hospital, Akure, ont été étudiés. Les isolats 
ont été caractérisés au niveau des espèces avec le kit Microbact 24E et criblés pour la production d'ESβL en utilisant 
le test à double disque (DDT) et les méthodes de disques combinés, AmpC en utilisant le test Hodge modifié (MHT) 
et le disque AmpC EDTA, et la production de carbapénémase en utilisant le MHT et test de disque EDTA. Le test de 
sensibilité aux antibiotiques (AST) a été effectué par la méthode de diffusion de disque de Kirby-Bauer                              
Résultats: Un total de 15 espèces de GNB ont été caractérisées. Le profil AST des isolats a révélé des taux de 
résistance élevés à l'ampicilline (94,5%), à la tétracycline (74,5%), au sulfaméthoxazole-triméthoprime (66,3%) et 
à la plus faible résistance à l'imipénème (10,9%). Une résistance à plusieurs médicaments (MDR) a été observée 
dans 93,6% tandis que 98,8% des isolats producteurs d'ESβL, AmpC et carbapénémase avaient de multiples indices 
de résistance aux antibiotiques (MAR) ≥ 0,2. La production d'ESβL a été détectée dans 53,9%, AmpC dans 20,9% et 
carbapénémase dans 25,2% des isolats. ESβL, AmpC ou carbapénémase ou la coproduction de deux ou des trois 
enzymes a été détectée dans 80 isolats (69,6%), tandis que seulement 10,0% ont produit les trois enzymes. 
Conclusion: L'isolement des bactéries MDR et des isolats co-producteurs d'enzymes d'hydrolyse des β-lactamines 
chez les individus immunodéprimés laisse présager de graves conséquences. Le dépistage systématique de ces 
enzymes dans les bactéries MDR sera très essentiel pour guider la mise en place d'une antibiothérapie appropriée et 
de mesures de contrôle des infections. 
Mots-clés: ESβL, AmpC, carbapénémase, VIH, MDR, isolats cliniques, MHT, DDST 
Introduction: 
 
 The use of antibiotics for the treatment 
of infections in humans and livestock usually 
result in the selection of pathogenic bacteria 
which become multiply resistant to them (1,2). 
Several strains of Gram-negative bacteria (GNB) 
are becoming resistant to practically all the 
commonly available antibacterial agents (3,4). 
Prominent among these GNB are the extended-
spectrum β-lactamase (ESβL) enterobacteria (5).  
 ESβLs are extended-spectrum β-lactam- 
ases that are capable of conferring bacterial 
resistance to the penicillins, first-, second-, and 
third-generation cephalosporins, as well as to 
aztreonam except cephamycins or carbapenems 
(6-9). ESβLs are mutants of TEM-1, TEM-2, and 
SHV-1 which act by hydrolysing β-lactam anti- 
biotics but are inhibited by β-lactamase inhi- 
bitors such as clavulanic acid (10), sulbactam, 
and tazobactam (11). However, the CTX-M type 
ESβLs have become more broadly distributed 
and globally prevalent (12-14).  
 AmpC β-lactamases are clinically signi-        
ficant because they may confer resistance to 
penicillins, cephalosporins (15), oxyimino-ceph- 
alosporins, cephamycins (16), and monobac- 
tams. Unlike ESβL, AmpC β-lactamase activity is 
not affected by clavulanic acid (17). Although 
reported with increasing frequency in clinical 
isolates, the actual occurrence rate of plasmid-
mediated AmpC β-lactamases in Enterobacteria- 
ceae remains unknown as many laboratories 
have difficulty in detecting these enzymes in 
clinical isolates (18). 
 Carbapenems are powerful, broad-spec- 
trum antibiotics, which are often considered to 
be the last line of defence in the treatment of 
infections caused by multidrug-resistant (MDR) 
GNB (19) because they are stable even in the 
presence of the extended-spectrum and AmpC 
β-lactamases. Carbapenemases are ESβLs pro- 
duced by resistant bacteria strains (20) which 
possess hydrolytic capacity against almost all β-
lactam antibiotics including carbapenems, and 
constitute the most versatile family of β-lactam- 
ases belonging to molecular classes-A, B and D.  
 ESβL and carbapenemase producing 
bacteria have become significant threats to 
patients in the hospital (21) and long-term care 
facilities as well as to immuno-compromised 
persons in the community. Worldwide, there is 
a rapid increase in the prevalence of ESβL, 
AmpC, and carbapenemase producing members 
of the family Enterobacteriaceae (21-27), and 
infections caused by them are associated with 
increased morbidity, mortality, and health care 
costs (21,28-31). Significant increase in the 
incidence of ESβL-related infections has been 
reported by various authors from around the 
world (32-36).  
 The increasing use of carbapenems to 
treat infections caused by ESβL-producing GNB 
is creating a ripple effect by causing increase in 
the prevalence of carbapenemase-producing 
bacteria. The screening and probable detection 
of ESβL production among bacteria isolates from 
immuno-compro- mised individuals as the case 
with HIV-infected patients, is of tremendous 
clinical significance because this may be                       
an epidemiologic marker of colonisation (37), 
which may invariably portend severe impli- 
cations in this group of patients. Again, these 
organisms exhibit co-resistance to many other 
classes of antibiotics because plasmids that 
encode ESβL genes most frequently carry genes 
encoding resistance to other drug classes, 
leading to failure in the treatment regimen and 
making therapeutic options limited (38).  
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 There are various studies on the 
prevalence of ESβL producing bacteria that have 
been conducted in different parts of Nigeria 
(7,39-46) with rates varying between 7.5% 
(43,47) and 58.6% (42), depending on the 
samples from which the isolates were obtained. 
A systematic review by Manenzhe et al., (48) 
reported that carbapenemase producers occur 
widely in Africa and have been reported in 
Nigeria (48). Le Terrier et al., (49) also recently 
reported the preponderance of carbapenemase-
producers in a Nigerian environment. Because of 
this, routine monitoring of clinical isolates for 
these traits with particular emphasis on patients 
who are immunocompromised is important. In 
this study, we evaluated the production of ESβL, 
AmpC, and carbapenemase among selected 
GNB isolates recovered from HIV-infected 
patients in two tertiary healthcare facilities in 
southwestern Nigeria using two phenotypic 
screening methods for the detection of each 
enzyme. 
Materials and method: 
Gram-negative isolates from participants: 
 The GNB isolates (n=115) investigated 
in this study were randomly selected from a 
collection of 316 GNB cultured from skin, throat, 
and rectal swabs of HIV seropositive patients in 
our previous study (50,51). The patients were 
recruited from two hospitals; Obafemi Awolowo 
University Teaching Hospitals Complex, Ile-Ife, 
and State Specialist Hospital, Akure, Ondo 
State, over a period of 18 months. Where two 
isolates from one patient were included, the 
strains were unique regarding species identi- 
fication or resistance pattern.    
 A preformed questionnaire indicating 
participant demographic information including 
age, gender, and other relevant information was 
used to collate data. Approval for the study was 
obtained from the Ethical Review Board of the 
Obafemi Awolowo University Teaching Hospital, 
Ile-Ife and the Management Board of Ondo 
State Specialist Hospital, Akure.  
Identification of the GNB isolates  
 The isolates, preserved in TSB with 15% 
glycerol broth at -20°C, were sub-cultured and 
purified on MacConkey agar (Oxoid, UK) for 
identification to species level. The inoculum was 
prepared by picking one or two well-isolated 
colonies and emulsifying in 5ml Ringer's solution 
(Oxoid, UK). The Microbact™ GNB 24E system 
was inoculated according to the manufacturer's 
instructions and incubated at 35±2°C for 18–24 
hours for oxidase-negative strains and 48 hours 
for oxidase-positive strains of the GNB. The 
wells were observed for colour change following 
the addition of appropriate reagents in line with 
the manufacturer's instruction. Each well was 
ascribed a numerical value indicating either a 
positive or negative reaction which was con- 
verted to a 9-digit code for final identification 
with the Microbact™ identification software 
version 2.04. The acceptable species identi- 
fication was ≥ 80.0% and ≤ 99.9%. 
Antibiotic susceptibility testing of GNB isolates 
 An in vitro antibiotic susceptibility assay 
was carried out on 110 of the 115 GNB isolates 
using the Kirby-Bauer disc diffusion method. 
Eleven antibiotics (Oxoid, UK) selected based on 
their frequent use in research and clinical 
therapy included ampicillin (10µg), chloram- 
phenicol (30µg), colistin (10µg), gentamicin (10 
µg), imipenem (10µg), nalidixic acid (30µg), 
nitrofurantoin (300 µg), piperacillin (30 µg), 
piperacillin/tazobactam (36µg), tetracycline (30 
µg) and trimethoprim/sulfamethoxazole (25µg). 
 Quality control was performed using 
Enterobacter aerogenes ATCC 13048 to confirm 
the consistency of materials, methods, and 
results. Interpretation of results as either 
susceptible, intermediate, or resistant was done 
using the zone diameter breakpoints recom- 
mended by Clinical and Laboratory Standards 
Institute (52). MDR pattern among the GNB 
isolates was defined as resistance to ≥ 1 agent 
in ≥ 3 antibiotic classes (53). Multiple antibiotic 
resistance (MAR) index for each isolate was 
evaluated by dividing the number of antibiotics 
to which isolate was resistant by the total 
number of antibiotics against which the bacteria 
isolate was tested (54).  
Detection of ESβL, AmpC, and carbapenemase in 
GNB isolates 
Phenotypic ESβL screening:  
 Screening for ESβL production was done 
using two methods: the double-disc synergy 
test (DDST) and the combination disc test 
methods. DDST was carried out, as described by 
Jarlier et al., (55). Using a sterile cotton-tipped 
applicator, Mueller-Hinton agar was inoculated 
with standardised test organism (0.5 McFarland 
turbidity standard) in Ringer's solution to give a 
semi-confluent growth. Discs containing 30µg 
each of aztreonam, ceftriaxone, cefotaxime, and 
ceftazidime, were placed 30mm apart (centre to 
centre) around a disc containing amoxicillin (20 
µg) plus clavulanic acid (10µg) on the agar 
surface, incubated at 35±2°C for 18-24 hours. 
Inhibition zone enhancement which indicates 
synergy between clavulanic acid and any one of 
test antibiotics, was regarded as presumptive 
ESβL production. Klebsiella pneumoniae ATCC 
700603 and Escherichia coli ATCC 25922 strains  
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served as positive and negative control strains 
respectively.    
 The combination disc test was per- 
formed using disc pairs containing cephalosporin 
(cefotaxime, ceftazidime, and cefpodoxime) 
with and without clavulanic acid in each case 
(56). Inoculation was carried out as described 
for DDST. The paired discs were placed on the 
inoculated plates with a distance of at least 
25mm separating them. The zones of inhibition 
were measured following overnight incubation 
at 35±2°C. Inhibition zone of ≥5mm or expan- 
sion by 50% around the combination disc 
(cephalosporin with clavulanic acid) compared 
to the cephalosporin disc alone was indicative of 
ESβL production (56). 
AmpC β-lactamase detection:    
 Screening for AmpC β-lactamase pro- 
duction was done by the AmpC disc test and 
modified Hodge test (MHT). AmpC disc test was 
carried out as described by Black et al., (57) 
with modification. AmpC discs were prepared in-
house by applying 20µl of a 0.5 M Tris-EDTA to 
sterile filter paper discs and dried, then 
rehydrated with 20µl saline just before use. 
Cefoxitin susceptible Escherichia coli ATCC 8739 
was used for lawn preparation on Mueller-Hinton 
agar. Cefoxitin disc (30µg) was placed on the 
inoculated media next to AmpC disc inoculated 
with the test isolate, with the inoculated disc 
face in contact with the agar surface. After 
overnight incubation at 35±2°C, an indentation 
or a flattening of the zone of inhibition, indi- 
cating enzymatic inactivation of cefoxitin was 
recorded as a positive result, while the absence 
of a distortion was recorded as a negative result.
 For the MHT test, a suspension of the 
cefoxitin susceptible strain of E. coli ATCC 8739 
was prepared, diluted 1:10 with physiological 
saline, and swabbed across a Mueller Hinton 
plate with a sterile cotton-tipped applicator. A 
30µg cefoxitin disc was placed at the centre of 
the test plate, and the test isolate was streaked 
in a straight line from the edge of the disc 
towards the edge of the plate. The plate was 
incubated overnight at 35±2°C. A positive test 
was indicated by the growth of the E. coli ATCC 
8739 along the line of streak of the test isolate 
towards the cefoxitin disc, while there was no 
growth of the E. coli on the line of streak in a 
negative result.  
Carbapenemase production:   
 The phenotypic screening for carba- 
penemase production was carried out using the 
MHT and the EDTA disc methods. The MHT was  
as described for 10µg imipenem but opposed to 
cefoxitin for AmpC screening. The E. coli strain 
ATCC 8739 used was also susceptible to 
imipenem. A positive test was indicated by a 
clover leaf-like indentation of the E. coli 8739 
growing along the growth streak of the test 
organism within the disc diffusion zone, while a 
negative test showed no growth of the E. coli 
8739 along the test organism growth streak 
within the disc diffusion zone. Quality control of 
the carbapenem discs was performed according 
to CLSI guidelines (52) by running MHT positive 
Klebsiella pneumoniae ATCC 1705 and MHT 
negative Klebsiella pneumoniae ATCC 1706 with 
each batch of the test.   
 For the EDTA disc test, a 0.5M EDTA 
solution was first prepared by dissolving 9.36g 
of EDTA and 6.05g of TRIS base in 50ml of 
distilled water in a 50ml volumetric flask, and its 
pH was adjusted to 8.0 by using NaOH. A 1µl of 
the 0.5M Tris-EDTA solutions was then dis- 
pensed onto sterile plain discs and the discs 
were used immediately. A lawn of the test 
isolate was plated on Mueller Hinton agar plate 
using a sterile cotton-tipped applicator and an 
imipenem disc (10µg) was placed in the centre 
of the plate with sterile forceps. The Tris-EDTA 
discs inoculated with colonies of the test strain 
were placed about 1mm to the imipenem disc 
with the inoculated side touching the agar. The 
plates were incubated at 35±2°C in ambient air 
for 16–24 hours. Indentation of the inhibition 
zone around the inoculated disc was indicative 
of the production of carbapenem-hydrolysing 
enzyme (positive test).  
Data analysis 
 Data on identification, susceptibility and 
enzyme production of the GNB isolates were 
analysed using the Statistical Package for the 
Social Sciences (SPSS) version 23.0, and results 
presented with frequency distribution tables and 




 The identification and distribution patt- 
ern of the 115 GNB bacteria isolates randomly 
selected for the study is shown in Table 1, with 
80 (69.6%) oxidase-positive and 35 (30.4%) 
oxidase-negative. The GNB isolates were chara-
cterized into 15 species (5 species for oxidase-
positive and 10 species for oxidase-negative). A 
total of 80 (69.6%) isolates produced ESβL, 
AmpC, carbapenemase, or co-produced either 
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Table 1. Distribution of selected Gram-negative isolates from HIV seropositive patients 
 








Oxidase Positive     
Actinobacillus sp. 1 (1.2) 0 (0.0) 1 (4.5) 2 (1.7) 
Pseudomonas fluorescens 25 6 (7.3) 0 (0.0) 0 (0.0) 6 (5.2) 
Burkholderia pseudomallei 10 (12.2) 1 (9.1) 6 (27.3) 17 (14.8) 
Aeromonas hydrophila 17 (20.7) 1 (9.1) 3 (13.6) 21 (18.2) 
Burkholderia cepacia 24 (29.3) 4 (36.3) 6 (27.3) 34 (29.5) 
Oxidase Negative     
Citrobacter freundii 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.9) 
Citrobacter youngae 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.9) 
Morganella morganii biogp 1 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.9) 
Photorhabdus asymbiotica 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.9) 
Pragia fontium  1 (1.2) 0 (0.0) 0 (0.0) 1 (0.9) 
Serratia marcescens 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.9) 
Proteus vulgaris 2 (2.4) 1 (9.1) 0 (0.0) 3 (2.6) 
Photorhabdus luminescens 25C  1 (1.2) 1 (9.1) 1 (4.5) 3 (2.6) 
Proteus mirabilis 7 (8.5) 1 (9.1) 2 (9.1) 10 (8.7) 
Pantoea agglomerans complex 8 (9.8) 2 (18.2) 3 (13.6) 13 (11.3) 
Total 82 (71.3) 11 (9.6) 22 (19.1) 115 
 
 
Antibiotic resistance profiles of GNB isolates 
 Out of the 115 GNB isolates, AST was 
performed only on 110. The AST profile of the 
isolates revealed that 94.5% (104/110) were 
resistant to ampicillin, 74.5% to tetracycline, 
and 66.3% to sulfamethoxazole-trimethoprim. 
The isolates exhibited lowest resistance rate to 
imipenem at 10.9% (12/110), closely followed 
by piperacillin/tazobactam at 13.6% and genta- 
micin at 15.5% (Table 2).   
 For the 80 enzyme-producing isolates, 
the least resistance rate was observed with 
piperacillin/tazobactam (11.3%), followed by 
imipenem (13.8%) and gentamicin (17.5%) 
while the highest resistance was to ampicillin, 
tetracycline, and sulfamethoxazole-trimetho- 
prim at 93.8%, 72.5%, and 70.0% respectively 
(Table 3).      
 All the isolates were resistant to at least 
one antibiotic and none was sensitive to all the 
antibiotics. Only 1 (0.9%) of the isolates tested 
was resistant to only one antibiotic and 6 (5.4%) 
to only two antibiotics. This implied a high level 
of MDR as 93.6% (103/110) were resistant to 
more than three classes of antibiotics (Fig 1).   
 
 
 For ESβL, AmpC, and carbapenemase-
producing strains, 82.5% (66/80) isolates were 
resistant to ≥ 4 classes of antibiotics. Only one 
isolate (1.25%), Aeromonas hydrophila was 
resistant to one antibiotic class (ampicillin), 6 
isolates (7.5%) to two classes, and 7 isolates 
(8.75%) to three antibiotic classes. The multiple 
antibiotic resistance index (MAR index) (Fig 2) 
showed that 97.3% of the total number of 
isolates and 98.8% of ESβL, AmpC, and carba- 
penemase-producing strains had MAR indices ≥ 
0.2.  
 
Co-production of ESβL, AmpC, and carbapenem- 
mase in GNB isolates 
Pattern of ESβL production  
 Using either one or both ESβL screening 
methods, 53.9% (62/115) of the GNB were 
ESβL producers; 32 (27.8%) were detected by 
the combination disc method (10 Burkholderia 
cepacia, 7 Aeromonas hydrophila, 5 Burkhold- 
eria pseudomallei, 5 Pantoea agglomerans com- 
plex, 3 Proteus mirabilis, and 1 each of Pseudo- 
monas fluorescens 25 and Serratia marcescens) 










Fig 1: Multiple resistance profile of selected Gram-negative isolates from HIV seropositive patients 
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while 42 isolates were detected with the double-
disc test (15 Burkholderia cepacia, 8 Pantoea 
agglomerans complex, 6 Burkholderia pseudo- 
mallei, 4 Aeromonas hydrophila, 3 each of Pro- 
teus mirabilis and Pseudomonas fluorescens 25, 
2 Photorhabdus luminescens 25C and 1 Photo- 
rhabdus asymbiotica). However, ESβL produc- 
tion was detected in 12 (10.4%) GNB isolates 
using both phenotypic methods, and these were 
5 Burkholderia cepacia, 3 Pantoea agglomerans 
complex, 2 Burkholderia pseudomallei, and 1 
each of Proteus mirabilis and Pseudomonas 
fluorescens 25 (Table 4). 
Pattern of AmpC β-lactamase production 
 The results of the AmpC β-lactamase 
enzyme detection for all the 115 selected GNB 
isolates revealed that 20.9% (24/115) were 
positive for AmpC β-lactamase production; 15 
with MHT alone (4 each of Burkholderia cepacia 
and Pantoea agglomerans complex, 3 Burkhold- 
eria pseudomallei, 2 Aeromonas hydrophila and 
1 each of Photorhabdus asymbiotica and Proteus 
mirabilis), 5 with the AmpC EDTA disc test alone 
(2 Burkholderia cepacia, 1 each of Aeromonas 
hydrophila, Burkholderia pseudomallei and 
Citrobacter freundii), and 4 with both tests (2 
Pantoea agglomerans complex, 1 Burkholderia 
cepacia, and 1 Proteus mirabilis) (Table 4). 
Pattern of carbapenemase production  
 Twelve of the 15 GNB species screened 
for carbapenemase production had at least one 
positive isolate in a specie except for Actino- 
bacillus sp., Pragia fontium, and Proteus vul- 
garis. Altogether, 29 GNB isolates (25.2%) were 
positive for carbapenemase production; 4 with 
the modified Hodge test alone; 23 with the EDTA 
disc test alone, and 2 isolates with both pheno- 
typic methods (Table 4).
  




Fig 3: Co-production profile for selected Gram-negative bacteria isolates from HIV seropositive patients 
 
Co-production of ESβL, AmpC, and carbapenem- 
mase:     
 The presence of either EsβL, AmpC, or 
carbapenemase or the co-production of two or 
all three enzymes was evaluated in a total of 80 
isolates. Only 8 (10.0%) isolates produced all 
three enzymes and these include 3 Burkholderia 
cepacia, 2 Pantoea agglomerans complex, and 1 
each of Burkholderia pseudomallei, Photo- 
rhabdus asymbiotica and Proteus mirabilis. The 
co-production of two enzymes (either EsβL/ 
AmpC, ESβL/carbapenemase, or carbapene- 
mase/AmpC) was detected in 19 (23.8%) GNB 
isolates while the last 53 (66.2%) GNB isolates 
produced only 1 enzyme each (Table 4 and Fig 
3). 
Resistance pattern to beta-lactam antibiotics 
and production of EsβL, AmpC, and carbapenem- 
mase among GNB isolates 
 In all 12 isolates resistant to imipenem, 
11 (10 of which were MDR) produced either 
ESβL, AmpC, carbapenemase, or co-produced 
two or all three enzymes. The last resistant 
isolate (Burkholderia cepacia) albeit MDR, did 
not produce any of the enzymes screened for. 
Four of them produced 2 enzymes each (carba- 
penemase and AmpC, 2; AmpC and ESβL, 2) 
while 5 produced only one enzyme each (ESβL, 
4; carbapenemase, 1). Only 2 of them (Burkhol- 
deria cepacia, 1; Photorhabdus asymbiotica, 1) 
produced all the three enzymes.  
 Seventy-five of the enzyme producers 
were resistant to ampicillin, 8 of them produced 
all three enzymes (all MDR), 48 produced only 
one of the three (ESβL, 38; AmpC, 4; carba- 
penemase, 6) while the remaining 19 isolates 
produced two out of the three enzymes 
(carbapenemase and AmpC, 7; AmpC and ESβL, 
4; and carbapenemase and ESβL,  8) (Table 3). 
Fifty-five of the isolates were resistant to 
piperacillin, 13 of them (all MDR) were negative 
for the three enzymes; 3 produced all the three 
enzymes; co-production of two enzymes was 
detected in 9 isolates (carbapenemase and 
AmpC, 4; AmpC and ESβL, 2; and carbapene- 
mase and ESβL, 4) while the remaining 30 
isolates produced only one enzyme each (ESβL, 
23; AmpC, 2; carbapenemase, 5). Six out of 
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fifteen isolates resistant to piperacillin/tazo- 
bactam did not produce any of the enzymes, 
while none produced all three. Four co-produced 
two enzymes (carbapenemase and AmpC, 1; 
AmpC and ESβL, 1; carbapenemase and ESβL, 
2) and 5 isolates produced one enzyme each 
(ESβL, 4; carbapenemase, 1). 
Discussion:  
 The rising prevalence of multiple 
resistance to previously effective antibiotics in 
GNB as a result of the production of enzymes 
that confer resistance to drugs has been a 
worrisome trend in the antibiotic treatment 
regimen for clinicians. This study was designed 
to phenotypically screen for the production of 
ESβLs, AmpC β-lactamase, and carbapenemase 
in selected GNB isolates cultured from HIV 
seropositive patients in southwestern Nigeria. 
We report a high level of resistance of the GNB 
to ampicillin (94.5%), a commonly prescribed 
beta-lactam antibiotic. This resistance is likely 
the result of beta-lactam hydrolysing enzymes 
as observed in this study. On the other hand, 
10.9% of the GNB were resistant to imipenem. 
This rate is lower than that reported by Dumaru 
et al., (58) where imipenem resistance rates for 
different species ranged between 0% to 60%. 
Again, Jalalvand et al., (21) reported resistance 
rates of 90% and 96.4% to imipenem and 
meropenem respectively.    
 However, resistance rate to piperacillin/ 
tazobactam and imipenem was 11.3% and 
13.8% respectively for the enzyme-producing 
GNB isolates. Yet, imipenem was the most 
active of all the antibiotics tested against the 
selected bacterial isolates. This high activity is 
in line with a previous study carried out by 
Ogbolu et al., (44) where imipenem was also the 
most effective of all the drugs tested. This 
highlights the fact that despite the rising 
prevalence of resistance to imipenem reported 
globally (59-62), it is still probably a highly 
effective antimicrobial agent in the event of 
therapeutic failure of other commonly pre- 
scribed antimicrobials particularly in this envir- 
onment where carbapenems have been reported 
as the established treatment choice for serious 
infections caused by ESβL producing GNB (63). 
 The proportion of MDR strains among 
the selected GNB isolates was high (93.6% of 
the isolates were MDR), and for the hydrolysing 
enzyme-producing strains, 91.3% were MDR. 
The high values of MAR indices for ESβL, AmpC, 
and carbapenemase-producing strains (98.8% 
with MAR ≥ 0.2) implies that these isolates were 
obtained from an antibiotic pressurised environ- 
ment. This is most likely because the isolates 
were recovered from HIV-infected patients who 
are immunocompromised and are probably in 
constant contact with the hospital environment. 
 A high rate of ESβL production (53.9%, 
62/115) was detected among the isolates in the 
study. The presence of ESβL trait in MDR GNB, 
particularly from clinical samples may be 
significant because it could be an indication of 
colonisation, with high potential for transfer 
from one patient to another (65). Colonisation 
by ESβL producing GNB has been linked to prior 
exposure to antibiotics and hospitalisation (65) 
which predisposes the host to infections caused 
by these organisms (31).   
 The frequency of AmpC β lactamase and 
carbapenemase producers were not as high as 
that of ESβL, with only 24 (20.9%) and 29 
(25.2%) respectively. However, the rate of ESβL 
and AmpC production in this study is much 
higher than previously reported rates in Nigeria; 
9.3% ESβL rate in 2007 (66), 15.8% ESβL and 
11.3% AmpC rates from northern Nigeria (7), 
and 15.8% ESβL and 9.6% AmpC rates in 
southern Nigeria (44). Our rates however agree 
with the report of Iroha et al., (42) and Yusuf et 
al., (46) both in Nigeria where the prevalence 
rate of ESβL production was 56.6% and 58.0% 
respectively. Very recently, Ugah and Udeani 
(67) reported ESβL production rate of 61.5% in 
Enterobacteriaceae isolates from south-eastern 
Nigeria. A study conducted in Iran (21) reported 
that 73.3% of carbapenem-resistant isolates 
were carbapenemase-producing ones. This high 
rate of production in our isolates could also be 
due to the immunocompromised nature of the 
patients. However, no ESβL production was 
detected in the two Citrobacter species, Morgan- 
ella morganii biogp 1, and Proteus vulgaris; and 
no AmpC production was detected in Citrobacter 
youngae, Morganella morganii biogp 1, Photo- 
rhabdus luminescens 25C, Pseudomonas fluore- 
scens 25 and Serratia marcescens.   
 Carbapenems have been reported to be 
the cornerstone of therapy for patients who 
have serious infections in which ESβL producers 
are implicated (63,68). The production of carba- 
penemases by some of the isolates although not 
remarkably high is quite worrisome because of 
the potential threat to the treatment regimen in 
the group of patients from which they were 
recovered. The production of ESβLs is a signi-    
ficant factor in the development of resistance of 
pathogenic GNB to broad-spectrum antibiotics, 
and the co-production of any of the three 
enzymes screened in this study portends serious 
implications especially for debilitated and 
immunosuppressed individuals such as HIV- 
infected patients. It also poses serious cha- 
llenges for the treatment of opportunistic 
infections which is quite common in this group 
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of patients due to their immuno-compromised 
state.      
 In this study, there was co-production of 
two or more of the enzymes among the isolates. 
The highest number of strains that produced at 
least one of the enzymes was Pantoea agglo- 
merans, formerly called, and identified by the 
Microbact 24E identification kit as Enterobacter 
agglomerans, 92.3% of the strains of this 
bacterium tested was a producer of at least one 
of the enzymes screened for and 2 of 13 strains 
tested produced all three enzymes. Pantoea 
agglomerans has been reported to be an oppor- 
tunistic pathogen, especially in the immuno-
suppressed persons such as neonates, pre- 
mature infants, burns or multiply traumatised 
patients, and patients with leukaemia or those 
undergoing immunosuppressive therapy, and 
not excluding HIV-infected individuals. It has 
been known to cause a range of infections, 
including wound, blood stream, and urinary 
tract infections. Infections are typically acquired 
from infected vegetation penetrating the skin, or 
hospital-acquired when associated with the use 
of contaminated intravenous products due to its 
ability to grow in commercial infusion fluids (69) 
or exposure of hospitalised, often immuno- 
compromised individuals to medical equipment 
or fluids contaminated with this bacterium (70). 
Bloodstream infection can lead to disseminated 
disease, mainly septic arthritis, but also end- 
ophthalmitis, periostitis, endocarditis and osteo- 
myelitis in humans (70).   
 Also worthy of note are the species, 
Burkholderia cepacia (formerly Pseudomonas 
cepacia) and Burkholderia pseudomallei (form- 
erly Pseudomonas pseudomallei) (71) in which 
70.6% of each was capable of producing at least 
one of the enzymes (24/34 and 12/17 respecti- 
vely). B. cepacia has been implicated in lung 
infections in patients with chronic granu- 
lomatous disease usually associated with pneu- 
monia and septicaemia which are often asso- 
ciated with high fatality (72-75), although they 
rarely cause infection in the immunocompetent 
host. B. cepacia is known to be resistant to most 
antimicrobial agents and can acquire resis- 
tance against many more. As such, effective 
therapies are not clear-cut; decisions on the 
treatment of B. cepacia infections are made on 
a case-by-case basis, and prevention of 
infection is, therefore, the focus at management 
(76-78). Burkholderia pseudomallei, on the 
other hand, is a highly pathogenic organism that 
is known to cause an infection called melioidosis, 
a potentially life-threatening infectious disease 
affecting mammals, including humans (79). The 
organism is intrinsically resistant to a wide 
range of antimicrobials (80), and treatment with 
ineffective antimicrobials may result in treat- 
ment failure leading to case fatality rates that 
may exceed 70% (81). Infections are often 
profoundly serious as clinical presentations may 
vary, and can culminate into diseases of the 
kidney, blood, heart, and other fatal disorders.  
 Proteus mirabilis is known to cause 90% 
of all Proteus infections in humans. It is thought 
that the majority of P. mirabilis urinary tract 
infections (UTI) are retrograde, resulting from 
the ascension of bacteria from the lower 
genitourinary tract, while others are by direct 
contact with infected persons, particularly in 
healthcare settings (82). Proteus species can 
also cause infection in the respiratory tract, eye, 
ear, nose, skin, throat, as well as in burns and 
wounds, mostly in hospitalised patients (82). 
Photorhabdus asymbiotica has been reported to 
be infectious to humans, although infections are 
mostly non-fatal (83). It is pertinent to note that 
the most prevalent GNB isolates recovered in 
our study were opportunistic pathogens that 
generally occur as contaminants on environ- 
mental surfaces within the healthcare setting. 
This could probably be adduced to the fact that 
the population from which the isolates were 
recovered were immunosuppressed by HIV 
infection, and as such are prone to colonisation 
by these non-virulent organisms. Again, these 
patients pay regular visits to the hospital for 
clinic visitations, monitoring of their health and 
immune status, and for treatments when ill or 
experiencing symptoms associated with AIDS-
related complexes.     
 The rapid detection of ESβLs in MDR 
organisms is highly essential to establish appro- 
priate antibiotic treatment, as well as implement 
infection control measures. The KPCs, and OXA-
48, are among the most prevalent carbapene- 
mases worldwide (84) and have been reported 
to cause outbreaks. NDM-1 can spread widely, 
as the plasmids that carry the NDM-1 gene are 
of broad host range, implying that they can 
disseminate easily between other members of 
the Enterobacteriaceae and unrelated species 
(85). The horizontal transfer of the NDM-1 gene 
itself between different plasmids in the same 
organism has been documented (86).   
 A major limitation of our study was the 
inability to confirm the genes encoding ESβL, 
AmpC, and carbapenemase in our isolates with 
a molecular method which is the 'gold standard' 
for detecting the presence of genes responsible 
for the expression of these enzymes. This is 
particularly concerning as previous reports have 
shown that organisms sensitive to carbapenems 
in the phenotypic test sometimes harbour 
carbapenemase gene detected by polymerase 
chain reaction. Infections associated with such 
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wrongly characterized isolates have resulted in 
treatment failures due to limited antibiotic 
options, sporadic outbreaks of infections caused 
by these organisms, extended hospital stays 
and ultimately higher cost of treatment, as well 
as increased morbidity and mortality. The use of 
combination therapy with two active drugs, 
colistin/tigecycline with intravenous fosfomycin, 
has been recommended for the treatment of 
infection caused by these organisms (87), but 
more recently, fosfomycin, aminoglycosides, 
and temocillin were reported to be relatively 
effective, and may well substitute carbapenems 
for therapy in the treatment of ESβL producing 
Enterobacteriaceae (63).  
 In conclusion, this study reports high 
rate of ESβL, AmpC, and carbapenemase co-
production in selected GNB pathogen. The EDTA 
method was more sensitive in detecting carba- 
penemase production while MHT was better at 
detecting AmpC enzyme. A high proportion of 
the enzyme producing GNB were MDR and had 
high MAR indices (98.8% with MAR ≥ 0.2), 
implying that the isolates had been exposed to 
a myriad of antibiotics. As such, routine checks 
for antibiotic hydrolysing enzyme production 
among bacterial isolates in clinical laboratories 
by phenotypic or genotypic methods should be 
embraced. Continuous surveillance, monitoring, 
screening, and reporting of isolates capable of 
producing these enzymes is essential to curtail 
the scourge of antibiotic resistance, as well as to 
understand better the mechanisms behind these 
traits. 
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